Preterm Labor Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 – 2020 and Forecast 2021 – 2027

$ PRICE - $ 3,000.00$ 8,900.00

Preterm Labor Treatment Market by Drugs (Tocolytic Drugs (Beta – Mimetic, Calcium Channel Blockers, NSAIDS), Corticosteroids, Magnesium Sulphate, Antibiotics, Others)), By Dosage Form (Tablets, Capsules, Injections), By End User (Hospitals, Pediatric and Neonatal Clinics, Nursing Homes, Pharmacy) and Geography (Latin America, North America, Asia Pacific, Middle East and Africa and Europe)

 

 

 


 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Preterm Labor Treatment Market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global market gives historical, current, and future market sizes (US$ Mn) of drugs (tocolytic drugs (beta – mimetic, calcium channel blockers, nsaids), corticosteroids, magnesium sulphate, antibiotics, others)), dosage form (tablets, capsules, injections), end user (hospitals, pediatric and neonatal clinics, nursing homes, pharmacy) and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of preterm labor treatment market In April 2016, AMAG Pharmaceuticals introduced FDA approved single dose, preservative free Makena to reduce risk of preterm birth. The flare-up of the Covid-19 pandemic and high danger of preterm birth related with Covid-19 disease has upsurged the interest for its testing arrangements. As indicated by the information distributed by CDC, pregnant women with Covid-19 are at increased danger for basic entanglements and may be at high danger for preterm birth.

Preterm Labor Treatment Market

MARKET SUMMARY
-
x
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR–x%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Preterm Labor Treatment Market Analysis

  • The major market participants are adopting the strategies such as mergers and acquisitions to position themselves as strong players.
  • In April 2016, AMAG Pharmaceuticals introduced FDA approved single dose, preservative free Makena to reduce risk of preterm birth.
  • In March 2015, GSK started Phase III clinical trials to evaluate the efficacy and safety of retosiban, an investigational oxytocin antagonist.
Market Leaders
  • Pfizer (U.S.)
  • Novartis (Switzerland)
  • Merck & Co (U.S.)
  • Sanofi (France)
  • Johnson & Johnson (U.S.)
  • GlaxoSmithKline (UK)
Preterm Labor Treatment Market

Drivers and Restraints

Increase in premature birth cases and rapid increase birthrate are major driving factors of preterm labor treatment market. As per WHO statistics, every year 15Mn babies are born. Increase in technological advancements, increasing demand for preterm therapeutics and diagnostics, increase in support of government, increase in R&D investments by market players are expected to propel the growth of preterm labor treatment market. However, lack of awareness, stringent regulatory framework, high costs associated with the treatment will hamper the growth of preterm labor treatment market.


Preterm Labor Treatment Market Regional Analysis

North America dominates the market

North America is the largest market followed by Europe in Preterm labor treatment market owing to presence of large number of market players, favourable government initiatives and regulatory framework, high incidence of preterm births. For instance, in 2007 a campaign was held in U.S. in the name of ‘Healthy People 2010’ which led to reduction of 12.7% to 7.6% preterm birth rate. Asia Pacific is anticipated to show significant growth in this market owing to increase in awareness and disposable income of developing economies, growing population pool, increased healthcare infrastructure.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Preterm Labor Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Pfizer (U.S.)
  • Novartis (Switzerland)
  • Merck & Co (U.S.)
  • Sanofi (France)
  • Johnson & Johnson (U.S.)
  • GlaxoSmithKline (UK)
  • AstraZeneca (UK)
  • Cipla (India)

Description

Preterm Labor Treatment Market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global market gives historical, current, and future market sizes (US$ Mn) of drugs (tocolytic drugs (beta – mimetic, calcium channel blockers, nsaids), corticosteroids, magnesium sulphate, antibiotics, others)), dosage form (tablets, capsules, injections), end user (hospitals, pediatric and neonatal clinics, nursing homes, pharmacy) and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of preterm labor treatment market In April 2016, AMAG Pharmaceuticals introduced FDA approved single dose, preservative free Makena to reduce risk of preterm birth. The flare-up of the Covid-19 pandemic and high danger of preterm birth related with Covid-19 disease has upsurged the interest for its testing arrangements. As indicated by the information distributed by CDC, pregnant women with Covid-19 are at increased danger for basic entanglements and may be at high danger for preterm birth.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX